论文部分内容阅读
目的:讨论研究重组人脑利钠肽用于治疗急性心肌梗死后心力衰竭的临床疗效与意义。方法:选取100例急性心梗后心力衰竭患者随机分为A、B两组,各50例。分别应用常规药物与联合重组人脑利钠肽治疗。比较两组患者不同药物治疗后心功能改善程度及治疗总有效率。结果:重组人脑利钠肽治疗总有效率94%显著高于常规治疗患者74%(P<0.05)。重组人脑利钠肽组患者心功能及B型利钠肽指标均显著优于常规组患者(P<0.05)。结论:应用重组人脑利钠肽治疗急性心梗后心力衰竭可显著改善患者心功能并减慢基础心律,可在短时间内缓解其各类不适症状。可在早期抑制心梗后左室重塑作用且患者不良反应少,安全系数较高。
Objective: To discuss the clinical efficacy and significance of recombinant human brain natriuretic peptide in the treatment of heart failure after acute myocardial infarction. Methods: 100 patients with acute heart failure after heart failure were randomly divided into A and B groups, 50 cases each. Were treated with conventional drugs and recombinant human brain natriuretic peptide respectively. The improvement of cardiac function and the total effective rate of the two groups of patients after treatment were compared. Results: The total effective rate of recombinant human brain natriuretic peptide was 94%, which was significantly higher than that of conventional treatment (74%, P <0.05). The cardiac function and B-type natriuretic peptide in recombinant human brain natriuretic peptide group were significantly better than those in the conventional group (P <0.05). Conclusion: Treatment of heart failure with recombinant human brain natriuretic peptide can significantly improve cardiac function and slow down basic rhythm in patients with acute myocardial infarction. It can relieve all kinds of symptoms in a short period of time. Left ventricular remodeling in the early stage of myocardial infarction can be suppressed and patients with less adverse reactions, higher safety factor.